Pathological findings in 2 cases of fatal 25I-NBOMe toxicity.
Jeffrey P Walterscheid, Garrett T Phillips, Ana E Lopez, Morna L Gonsoulin, Hsin-Hung Chen, Luis A Sanchez
American Journal of Forensic Medicine & Pathology March 1, 2014 DOI: 10.1097/paf.0000000000000082 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Case report Peer reviewed |
|---|---|
| Sample size | 2 |
| Population | Two decedents who attended rave parties and ingested 25I-NBOMe |
| Key findings | Two deaths after 25I-NBOMe ingestion showed a consistent pattern of violent agitation, external injuries, and rapid deterioration. |
Abstract
The research compound 25I-NBOMe, also known as CIMBI-5 or INBMeO, was created in academic laboratories as a potent serotonin 2A receptor agonist. Because of its high affinity and ambiguous legal status, recreational drug enthusiasts have used this compound as a powerful alternative to other hallucinogenic drugs such as lysergic acid diethylamide. We report 2 deaths after 25I-NBOMe ingestion by decedents who attended separate "rave" parties. The first case involved a 21-year-old male who admitted taking "acid" to his friend. A sudden violent rage caused him to flail about, and he subsequently became unresponsive. The postmortem examination revealed numerous external injuries that were consistent with physical aggression. The second case involved a 15-year-old female who was socializing outside a rave party, became ill, and rapidly deteriorated as her friend transported her to the hospital. The postmortem assessment was similar to the first case in that external contusions featured prominently. Comprehensive toxicology screens in both cases revealed only evidence of marijuana use. A deeper analysis using time-of-flight mass spectrometry revealed the presence of 25I-NBOMe, which was further confirmed by tandem-mass spectrometry. The behavior and injuries in these cases reveal a consistent pattern preceding fatal 25I-NBOMe toxicity.
Citations in the library
Cited by 35
- Designer drugs: mechanism of action and adverse effects Archives of Toxicology April 1, 2020
- Receptor interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives of 2,5-dimethoxy-substituted phenethylamines (2C drugs). Neuropharmacology December 1, 2015
- Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signalling Swiss Medical Weekly January 11, 2015
- Designer drugs 2015: assessment and management Addiction Science & Clinical Practice March 11, 2015
- Pharmacology and Toxicology of N-Benzylphenethylamine ("NBOMe") Hallucinogens. Current Topics in Behavioral Neurosciences 2017
and 30 more in the library
Cites 9
- 25C-NBOMe--new potent hallucinogenic substance identified on the drug market. Forensic Science International April 10, 2013
- Analytical characterization of three hallucinogenic N-(2-methoxy)benzyl derivatives of the 2C-series of phenethylamine drugs. Drug Testing and Analysis August 1, 2013
- Radiosynthesis and Evaluation of 11C-CIMBI-5 as a 5-HT2A Receptor Agonist Radioligand for PET Journal of Nuclear Medicine October 18, 2010
- Morbidity involving the hallucinogenic designer amines MDA and 2C-I. Journal of Forensic Sciences November 1, 2009
- 4‐Aryl‐Substituted 2,5‐Dimethoxyphenethylamines: Synthesis and Serotonin 5‐HT2AReceptor Affinities Chemistry & Biodiversity May 1, 2009
and 4 more in the library